Impact of Physiologically Based Pharmacokinetic Models on Regulatory Reviews and Product Labels: Frequent Utilization in the Field of Oncology-Reference-Cited by-同舟云学术

Impact of Physiologically Based Pharmacokinetic Models on Regulatory Reviews and Product Labels: Frequent Utilization in the Field of Oncology

Published:2017-03-15 Issue:5 Volume:101 Page:597-602
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Yoshida K¹,Budha N¹,Jin JY¹

Affiliation:

1. Department of Clinical Pharmacology; Genentech Research and Early Development; South San Francisco California USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference5 articles.

1. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK;Wagner;CPT Pharmacometrics Syst. Pharmacol.,2015

2. European Medicines Agency Draft guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf 2016

3. Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance;Jamei;Curr. Pharmacol. Rep.,2016

4. Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency;Luzon;Clin. Pharmacol. Ther.,2016

5. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective;Jones;Clin. Pharmacol. Ther.,2015

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations;The Journal of Clinical Pharmacology;2024-06-19

2. Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach;CPT: Pharmacometrics & Systems Pharmacology;2024-01-30

3. Applications of Advanced Natural Language Processing for Clinical Pharmacology;Clinical Pharmacology & Therapeutics;2024-01-24

4. The Interplay of Permeability, Metabolism, Transporters, and Dosing in Determining the Dynamics of the Tissue/Plasma Partition Coefficient and Volume of Distribution—A Theoretical Investigation Using Permeability-Limited, Physiologically Based Pharmacokinetic Modeling;International Journal of Molecular Sciences;2023-11-12

5. Development and application of a PBPK modeling strategy to support antimalarial drug development;CPT: Pharmacometrics & Systems Pharmacology;2023-08-16